Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Nov;68(5):916–919. doi: 10.1038/bjc.1993.454

Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517).

L Capolongo 1, G Melegaro 1, M Broggini 1, N Mongelli 1, M Grandi 1
PMCID: PMC1968750  PMID: 8105866

Abstract

Human colon adenocarcinoma cells (LoVo) resistant to the new antitumor agent FCE 24517 [benzoyl-mustard derivative of distamycin A] (LoVo/24517) are resistant to the selecting agent and related molecules as well as to vinblastine, with marginal or no resistance to other antitumour drugs. Treatment with verapamil, tamoxifen, nicergoline or cyclosporin A only partially restores the activity of FCE 24517 against LoVo/24517 cells. Such results suggest that resistance mechanisms possible specific for this class of compounds are operating.

Full text

PDF
916

Images in this article

917Figure 2
on p.917

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arcamone F. M., Animati F., Barbieri B., Configliacchi E., D'Alessio R., Geroni C., Giuliani F. C., Lazzari E., Menozzi M., Mongelli N. Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives. J Med Chem. 1989 Apr;32(4):774–778. doi: 10.1021/jm00124a008. [DOI] [PubMed] [Google Scholar]
  2. Broggini M., Erba E., Ponti M., Ballinari D., Geroni C., Spreafico F., D'Incalci M. Selective DNA interaction of the novel distamycin derivative FCE 24517. Cancer Res. 1991 Jan 1;51(1):199–204. [PubMed] [Google Scholar]
  3. Broggini M., Ponti M., Ottolenghi S., D'Incalci M., Mongelli N., Mantovani R. Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements. Nucleic Acids Res. 1989 Feb 11;17(3):1051–1059. doi: 10.1093/nar/17.3.1051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dinota A., Tazzari P. L., Michieli M., Visani G., Gobbi M., Bontadini A., Tassi C., Fanin R., Damiani D., Grandi M. In vitro bone marrow purging of multidrug-resistant cells with a mouse monoclonal antibody directed against Mr 170,000 glycoprotein and a saporin-conjugated anti-mouse antibody. Cancer Res. 1990 Jul 15;50(14):4291–4294. [PubMed] [Google Scholar]
  5. Drewinko B., Romsdahl M. M., Yang L. Y., Ahearn M. J., Trujillo J. M. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res. 1976 Feb;36(2 Pt 1):467–475. [PubMed] [Google Scholar]
  6. Geroni C., Pesenti E., Tagliabue G., Ballinari D., Mongelli N., Broggini M., Erba E., D'Incalci M., Spreafico F., Grandi M. Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies. Int J Cancer. 1993 Jan 21;53(2):308–314. doi: 10.1002/ijc.2910530223. [DOI] [PubMed] [Google Scholar]
  7. Grandi M., Geroni C., Giuliani F. C. Isolation and characterization of a human colon adenocarcinoma cell line resistant to doxorubicin. Br J Cancer. 1986 Sep;54(3):515–518. doi: 10.1038/bjc.1986.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gros P., Ben Neriah Y. B., Croop J. M., Housman D. E. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature. 1986 Oct 23;323(6090):728–731. doi: 10.1038/323728a0. [DOI] [PubMed] [Google Scholar]
  9. Kopka M. L., Yoon C., Goodsell D., Pjura P., Dickerson R. E. The molecular origin of DNA-drug specificity in netropsin and distamycin. Proc Natl Acad Sci U S A. 1985 Mar;82(5):1376–1380. doi: 10.1073/pnas.82.5.1376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Meador J., Sweet P., Stupecky M., Wetzel M., Murray S., Gupta S., Slater L. Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129. Cancer Res. 1987 Dec 1;47(23):6216–6219. [PubMed] [Google Scholar]
  11. Montecucco A., Fontana M., Focher F., Lestingi M., Spadari S., Ciarrocchi G. Specific inhibition of human DNA ligase adenylation by a distamycin derivative possessing antitumor activity. Nucleic Acids Res. 1991 Mar 11;19(5):1067–1072. doi: 10.1093/nar/19.5.1067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pezzoni G., Grandi M., Biasoli G., Capolongo L., Ballinari D., Giuliani F. C., Barbieri B., Pastori A., Pesenti E., Mongelli N. Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A. Br J Cancer. 1991 Dec;64(6):1047–1050. doi: 10.1038/bjc.1991.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ramu A., Glaubiger D., Fuks Z. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res. 1984 Oct;44(10):4392–4395. [PubMed] [Google Scholar]
  14. Rogan A. M., Hamilton T. C., Young R. C., Klecker R. W., Jr, Ozols R. F. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science. 1984 Jun 1;224(4652):994–996. doi: 10.1126/science.6372095. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES